The same group has also reported that the combined cannabinoids (THC + CBD) can improve memory impairment in APPxPS1 mice with an advanced stage of AD, which is not associated with APP processing or reducing glial activity, leading to Aβ deposition as observed in the early stages but via reduced GluR2/3 and increased levels of GABA-A Rα1 (Aso et al., 2016). This evidence concerns the gene APP and Alzheimer disease.